all report title image
  • Published On : Nov 2020
  • Code : CMI2394
  • Industry : Biotechnology
  • Pages : 204
  • Formats :

Rising demand for human biologics cannot be fulfilled by currently used mammalian cell culture production platforms, as these platforms are highly expensive and have limited scalability. However, recent developments in plant expression vectors, downstream processing, and glycoengineering have established plants as a superior alternative to biologics production. Plants not only offer the traditional benefits of proper eukaryotic protein modification, but also have the potential to develop biologics at a lower cost with high scalability. They increase the production of biologics at unprecedented speed and also helps in controlling potential pandemics such as covid-19, Ebola and others for better efficacy or safety.

Plant-based biologics is expected to be the next major commercial development in the field of biotechnology. Some of the advantages offered by plant-based biologics in terms of product safety, production scale and economy, ease of storage, and distribution cannot be fulfilled at same time by any other current commercial system. Plant-based biologics also provide the opportunity to supply low-cost drugs and vaccines to the emerging economies such as Argentina, Brazil, China, India, Indonesia, Mexico, and others.

Plant-based Biologics Market – Impact of Coronavirus (Covid-19) Pandemic

The rapid spread of Covid-19 infection has positively impacted the plant-based biologics market as it has increased the demand of plant-based vaccines for prevention of Covid-19 infection. Rapid development of novel diagnostics, therapeutics, and vaccines is needed to mitigate spread of the SARS-CoV-2 virus and prevent future reoccurrences. Moreover, establishment of safe, efficacious vaccine platforms will be critical to develop a stronger level of preparedness for future outbreaks. Multiple vaccine technology platforms are being employed by companies such as iBio Inc., PlantForm to address the COVID-19 pandemic. More traditional approaches are based on live or killed viruses, while newer solutions rely on recombinant DNA or messenger RNA (mRNA). AstraZeneca, Pfizer, Moderna, and CureVac, among many others, are progressing new vaccines at an accelerated pace, with some already in late-stage clinical trials with tens of thousands of participants.

The plant-based biologics market is estimated to be valued at US$ 19.4 million in 2020 and is expected to exhibit a CAGR of 3.4% during the forecast period (2020-2027).

Figure 1. Plant-based Biologics Market Share (%) Regional Analysis, 2027

Plant Based Biologics  | Coherent Market Insights

Robust pipeline of plant-based biologics are expected to boost growth of the plant-based biologics market

Major players in the market have a number of biopharmaceuticals products in clinical trials, or products that are awaiting approval from regulatory authorities. Thus, the robust pipeline of biopharmaceutical products is expected to significantly drive growth of the global plant-based biologics market in near future. For instance, Protalix Biotherapeutics’s, a global plant based biologics drug manufacturing company one major plant-based drug candidates in their pipeline – Pegunigalsidase alfa is designed to be a plant cell culture-expressed and a chemically modified version of the recombinant alpha-Galactosidase-A protein. In clinical research, pegunigalsidase alfa has exhibited a favorable circulatory half-life with targeted enzyme activity in organs affected by Fabry disease. The product is in phase 3 clinical trial.

Furthermore, iBio, Inc. is a plant–based biologics manufacturing company, which manufactures monoclonal antibodies, antigens, bioinks, and other recombinant proteins using FastPharming technologies has three plant-based biologics, which are in preclinical stage. In terms of human disease, IBIO-100 targets fibrosis, a leading cause of organ failure worldwide. IBIO-200 is a virus-like particle (VLP) vaccine designed as a rapid medical countermeasure solution to the COVID-19 outbreak. IBIO-201 is a vaccine targeting COVID-19 using the patented LicKM platform. Hence, such product developments are expected to positively impact the global plant-based biologics market growth.

CMI table icon

Plant-based Biologics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: Over US$ 19.4 Mn
Historical Data for: 2017 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 3.4% 2027 Value Projection: Over US$ 24.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Monoclonal Antibodies, Alpha Interferon, Glucocerebrosidase, Vaccines, Others.
  • By Source Type: Carrot, Tobacco Leaves, Rice Seeds, Alfalfa, Others.
  • By Disease Indication: Gaucher Disease, Tooth Decay, Hepatitis, Lymphoma, Others.
Companies covered:

Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V.

Growth Drivers:
  • Advantages of plant-based biologics
  • Robust pipeline of plant-based biologics
Restraints & Challenges:
  • Stringent regulatory approval process, and potential risks

Plant-based Biologics Market – Restraints

The stringent regulatory guidelines for the production of plant-based biologics is one of the major factors that is expected to restrain growth of the plant-based biologics market over the forecast period. Moreover, concerns regarding contamination and environmental risks is another factor that is expected to hinder growth of the market. For instance, ProdiGene, Inc. Texas, a U.S.-based company introduced large-scale production of transgenic maize that produces trypsin. However, the U.S. Department of Agriculture (USDA) discovered that plant remnants from a previous ProdiGene trial had contaminated a nearby conventional field. ProdiGene was fined US$ 250,000 and US$ 3 million to cover the cleanup operation of mishandling the field test. The punitive action forced ProdiGene into bankruptcy. This event represented a significant setback to the commercial use of plant molecular farming (PMF).

Plant-based Biologics Market – Regional Analysis

On the basis of region, the global plant-based biologics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to be the most lucrative region in the plant-based biologics market over the forecast period. This is owing to the presence of various private and government research organizations focused on R&D activities to develop plant-based biologics in this region. For instance, Fraunhofer Center for Molecular Biotechnology completed phase I clinical trials for the study of safety and immunogenicity of plant-derived recombinant protective antigen (Biological: PA83-FhCMB) for anthrax vaccine in healthy adults in the year 2015. Furthermore, key players in North America are focused on conducting clinical trials to develop plant-based biologics for the treatment of various chronic diseases, which is further expected to drive growth of the plant-based biologics market in this region.

In addition, Latin America plant-based biologics market is expected to witness significant growth during the forecast period, owing to launch and construction of manufacturing facilities for plant-based biologics. For instance, in June 2017, Brazil-based Axis Biotec Brasil announced the construction of tobacco leaves-based biopharmaceutical expression and manufacturing facility in Brazil for the development of biosimilar and protein and biobetter drugs for the Brazilian market.

Figure 2. Plant-based Biologics Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Plant Based Biologics  | Coherent Market Insights

Plant-based Biologics Market - Competitive Landscape

Key players operating in the global plant-based biologics market include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V.

Plant-based biologics are biologic drugs that are manufactured by using plant molecular farming. They are also known as plant-made biologics (PMB). The applications and advantages of plant-based biologics have stretched beyond the traditional boundaries of vaccines and therapeutic proteins. For instance, bacterial colicins derived from plants in 2015 were recently proven effective as food additives for controlling pathogenic bacteria in food products. These colicins are highly effective (even when used in lower concentrations) to fight against all the pathogenic Escherichia coli strains that cause food poisoning. Moreover, it costs around US$ 1.00 for manufacturing one gram of purified colicins, which is commercially viable.

Market Dynamics

The increasing demand for biologics for various chronic diseases and rising investments in R&D for the production of biologics are expected to contribute significantly to the growth of plant-based biologics market. For instance, according to the Biotechnology Innovation Organization (BIO) 2015, over 250 biologic therapies and vaccines have changed the lives of hundreds of millions of patients. Moreover, according to the same source, over 900 biologics are currently (2018) under the stage of development for over 100 diseases in the U.S. Furthermore, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), 2016, member companies invested around US$ 58.8 billion in research and development in 2015, of which, majority of the investments was made by all the biopharmaceutical companies in the U.S. for the treatment of rare diseases.

Many biopharmaceutical companies are focused on developing plant-made pharmaceuticals using various plants such as tobacco, duckweed, moss, alfalfa, and other plants, which is expected to propel growth of the plant-based biologics market. For instance, in September 2015, LeafBio, Inc., the commercial partner of Mapp Biopharmaceutical, Inc. (Mapp), was granted fast track designation by the U.S. Food and Drug Administration (FDA) for their plant-made drug ZMapp for the treatment of Ebola virus disease.

However, stringent regulatory guidelines for the production of plant-based biologics is one of the major factors restraining growth of the plant-based biologics market. Moreover, concern regarding contamination and environmental risks is another factor restraining growth of the market.

Key features of the study:

  • This report provides in-depth analysis of the global plant-based biologics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global plant-based biologics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global plant-based biologics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for plant-based biologics market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Plant-based Biologics Market, By Product Type:
    • Monoclonal Antibodies
    • Alpha Interferon
    • Glucocerebrosidase
    • Vaccines
    • Others
  • Global Plant-based Biologics Market, By Source Type:
    • Carrot
    • Tobacco Leaves
    • Rice Seeds
    • Alfalfa
    • Others
  • Global Plant-based Biologics Market, By Disease Indication:
    • Gaucher Disease
    • Tooth Decay
    • Hepatitis
    • Lymphoma
    • Others
  • Global Plant-based Biologics Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product Type:
        • Monoclonal Antibodies
        • Alpha Interferon
        • Glucocerebrosidase
        • Vaccines
        • Others
      • By Source Type:
        • Carrot
        • Tobacco Leaves
        • Rice Seeds
        • Alfalfa
        • Others
      • By Disease Indication:
        • Gaucher Disease
        • Tooth Decay
        • Hepatitis
        • Lymphoma
        • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product Type:
        • Monoclonal Antibodies
        • Alpha Interferon
        • Glucocerebrosidase
        • Vaccines
        • Others
      • By Source Type:
        • Carrot
        • Tobacco Leaves
        • Rice Seeds
        • Alfalfa
        • Others
      • By Disease Indication:
        • Gaucher Disease
        • Tooth Decay
        • Hepatitis
        • Lymphoma
        • Others
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product Type:
        • Monoclonal Antibodies
        • Alpha Interferon
        • Glucocerebrosidase
        • Vaccines
        • Others
      • By Source Type:
        • Carrot
        • Tobacco Leaves
        • Rice Seeds
        • Alfalfa
        • Others
      • By Disease Indication:
        • Gaucher Disease
        • Tooth Decay
        • Hepatitis
        • Lymphoma
        • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product Type:
        • Monoclonal Antibodies
        • Alpha Interferon
        • Glucocerebrosidase
        • Vaccines
        • Others
      • By Source Type:
        • Carrot
        • Tobacco Leaves
        • Rice Seeds
        • Alfalfa
        • Others
      • By Disease Indication:
        • Gaucher Disease
        • Tooth Decay
        • Hepatitis
        • Lymphoma
        • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product Type:
        • Monoclonal Antibodies
        • Alpha Interferon
        • Glucocerebrosidase
        • Vaccines
        • Others
      • By Source Type:
        • Carrot
        • Tobacco Leaves
        • Rice Seeds
        • Alfalfa
        • Others
      • By Disease Indication:
        • Gaucher Disease
        • Tooth Decay
        • Hepatitis
        • Lymphoma
        • Others
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product Type:
        • Monoclonal Antibodies
        • Alpha Interferon
        • Glucocerebrosidase
        • Vaccines
        • Others
      • By Source Type:
        • Carrot
        • Tobacco Leaves
        • Rice Seeds
        • Alfalfa
        • Others
      • By Disease Indication:
        • Gaucher Disease
        • Tooth Decay
        • Hepatitis
        • Lymphoma
        • Others
  • Company Profiles
    • Leaf Expression Systems*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Zea Biosciences
    • Planet Biotechnology Inc.
    • InVitria
    • PlantForm Corporation
    • IBIO, Inc.
    • Mapp Biopharmaceutical, Inc.
    • Pfizer Inc.
    • Ventria Bioscience Inc.
    • Medicago Inc.
    • Eleva GmbH
    • Kentucky Bioprocessing, LLC
    • Solarvest Bioenergy Inc.
    • Byondis B.V.

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The plant-based biologics market is expected to register a CAGR of market is 3.4% during the forecast period (2020-2027).
The value of plant-based biologics market is estimated to be US$ 19.4 million in 2020.
The prominent players in the global plant-based biologics market include Leaf Expression Systems, Zea Biosciences, Planet Biotechnology Inc., InVitria, PlantForm Corporation, IBIO, Inc., Mapp Biopharmaceutical, Inc., Pfizer Inc., Ventria Bioscience Inc., Medicago Inc., Eleva GmbH, Kentucky Bioprocessing, LLC, Solarvest Bioenergy Inc., and Byondis B.V.
The plant-based biologics market is expected to be valued at US$ 24.9 million in 2027.
North America is the major region in the plant-based biologics market.
The increasing advantages of plant-based biologics and robust pipeline of plant-based biologics are expected to drive growth of the plant-based biologics market in the forecast period.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo